CTH 501
Alternative Names: CTH-501Latest Information Update: 29 Aug 2025
At a glance
- Originator Cartherics
- Class CAR-NK cell therapies; Gene therapies
- Mechanism of Action Natural killer cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Endometriosis
Most Recent Events
- 19 Aug 2025 Preclinical trials in Endometriosis in Australia (Parenteral) (Cartherics Pipeline, August 2025)